http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106924172-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4748 |
| filingDate | 2017-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106924172-B |
| titleOfInvention | Huperzine A lyotropic liquid crystal preparation and preparation method thereof |
| abstract | The invention provides a huperzine A lyotropic liquid crystal preparation and a preparation method thereof, wherein the huperzine A lyotropic liquid crystal preparation comprises the following components in parts by weight: 0.12-0.7 part of huperzine A, 10-18 parts of organic solvent, 12-70 parts of phospholipid and 12-59.5 parts of grease. The invention adopts phospholipid, grease and organic solvent as huperzine A carrier, effectively improves the solubility of huperzine A, further overcomes the defect that huperzine A is difficult to dissolve in water, is beneficial to the exertion of the drug effect of huperzine A, and can form lyotropic liquid crystal when being injected into human body under the condition of limited component dosage proportion, thereby increasing the adhesiveness of the drug and the preparation, slowing down the diffusion speed of the drug, increasing the administration period, reducing the administration times and greatly improving the compliance of patients. |
| priorityDate | 2017-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.